You are here:

palonosetron (Aloxi)

Advice

following an abbreviated submission

palonosetron (Aloxi®) is accepted for use within NHS Scotland.

Indication under review: prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, in paediatric patients 1 month of age and older.

A phase III double blind study demonstrated non-inferiority of palonosetron to another 5-HT3 antagonist in paediatric patients.

Drug Details

Drug Name: palonosetron (Aloxi)
SMC Drug ID: 1073/15
Manufacturer: Chugai Pharma UK Ltd
Indication: Prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, in paediatric patients 1 month of age and older.
BNF Category:
Sub Category: 4.6 Drugs used in nausea and vertigo
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 10 August 2015

Back